London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...

BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 4th, before market open. The consensus EPS Estimate is -$1.65 (+50.9% Y/Y) and the consensus Revenue Estimate is ...

Analysts estimate that BioNTech will report an earnings per share (EPS) of $-1.31. The market awaits BioNTech's announcement, ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) – Stock analysts at HC Wainwright dropped their Q3 2025 earnings estimates for BioNTech in a note issued to investors on Wednesday, June 25th.

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Throughout the last three months, 11 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings ...

In Germany, a court in the city of Düsseldorf ruled in March that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) violated a COVID-19 vaccine patent asserted by Moderna (MRNA).

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...